Genexine Rises 7.65% Amid Uptrend in Gene Therapy/Analysis Themes

On the 19th, the gene therapy/analysis theme showed strength by rising 3.33% compared to the previous day, with Genexine, a related stock drawing attention, soaring 7.65% from the previous day. Genexine is known as a company specializing in the development of biopharmaceuticals.

[Graph] Major stock price changes in the gene therapy/analysis theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Genexine's quant financial score was 5.84 points, ranking 15th in quant financial ranking within the gene therapy/analysis theme. This can be interpreted as Genexine having relatively low investment attractiveness from a financial perspective. On the other hand, Theragen Etex ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the robo algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.